The National Vascular Disease Prevention Alliance (NVDPA) Guidelines for the management of absolute cardiovascular disease risk are the current Australian guidelines, which contain recommendations on assessment of an individual’s absolute risk of having a primary cardiovascular disease (CVD) event in the next 5 years, and on optimal management based on this assessment.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Canberra: NVDPA, 2012. https://www.heartfoundation.org.au/images/uploads/publications/Absolute-CVD-Risk-Full-Guidelines.pdf (accessed Nov 2016).
- 2. Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular disease events and blood pressure- and lipid-lowering therapy in Australia. Med J Aust 2016; 204: 320. <MJA full text>
- 3. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347: f5680.
- 4. Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.